Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

Number of employees : 234 people.
Sales per Business
2019
CHF (in Million)%
MMX Products28.0440.3%
Licence Fees, Up - front Fees and Milestones13.9620.1%
Royalties11.5416.6%
Generic Products and Specialty Drugs9.1813.2%
Marketed Products - Eleview2.373.4%
Related Services1.932.8%
Other Revenues from Sales1.402%
GI Genius1.091.6%
Sales per region
20182019Delta
CHF (in Million)%CHF (in Million)%
Italy75.76100%69.51100% -8.25%
Managers
NameAgeSinceTitle
Alessandro E. Della Ch562014Chief Executive Officer & Executive Director
Mauro Severino Ajani642006Executive Chairman
Giuseppe Cipriano622001Chief Operating Officer
Niall Donnelly45-Chief Financial Officer & Head-Investor Relations
Davide Malavasi46-Director-Qualified Person & Technical
Stefano Selva-2020Chief Scientific Officer
Kevin Joseph Donovan602016Independent Non-Executive Director
Dieter A. Enkelmann612006Independent Non-Executive Director
Maria Grazia Roncarolo, Dr.652012Independent Non-Executive Director
Hans Christoph Tanner, Dr.692020Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 15,037,483 6,889,419 45.8% 251,637 1.7% 45.8%
Shareholders
NameEquities%
Mauro Severino Ajani 5,583,209 37.1%
Gerald Herz 1,204,182 8.01%
dievini Hopp BioTech holding GmbH & Co. KG 786,361 5.23%
Cosmo Pharmaceuticals N.V. 521,767 3.47%
AMG Fondsverwaltung AG 409,588 2.72%
UBS Asset Management Switzerland AG 363,791 2.42%
The Vanguard Group, Inc. 193,758 1.29%
Baillie Gifford & Co. 174,076 1.16%
Norges Bank Investment Management 141,947 0.94%
BlackRock Fund Advisors 95,707 0.64%
Holdings
NameEquities%Valuation
Cassiopea S.p.A. (SKIN) 4,515,45742.0%221,696,115 USD
Cosmo Pharmaceuticals N.V. (COPN) 521,7673.47%42,183,114 USD
Acacia Pharma Group (ACPH) 17,500,14020.0%37,712,277 USD
RedHill Biopharma Ltd. (RDHL) 69,000,01019.6%34,287,485 USD
Paion AG (PA8) 5,238,2257.85%12,447,542 USD
Company contact information
Cosmo Pharmaceuticals NV
Riverside II
Sir John Rogerson's Quay
Dublin 2

Phone : +353.1.8170370
Fax : +353.1.8230718
Web : http://www.cosmopharma.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.10.17%1 356
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389
ABBVIE INC.18.12%184 633
NOVO NORDISK A/S8.55%155 951
BRISTOL-MYERS SQUIBB COMPANY-2.79%141 008
ASTRAZENECA PLC2.54%136 635
ELI LILLY AND COMPANY10.82%132 044
AMGEN INC.-6.63%129 265
SANOFI-6.16%127 199
GLAXOSMITHKLINE PLC-22.37%90 971
CHUGAI PHARMACEUTICAL CO., LTD.50.12%79 458
JIANGSU HENGRUI MEDICINE CO., LTD.17.90%69 083
DAIICHI SANKYO COMPANY, LIMITED53.32%68 872
BAYER AG-33.15%56 677
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.55%56 107
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED43.82%28 440
ASTELLAS PHARMA INC.-20.67%26 407